معرفی
Gabor Halmos is a University Professor at the University of Debrecen, where he serves as Head of the Department of Biopharmacy and Vice Dean. His extensive academic career spans over three decades with 212 scientific publications to his name, demonstrating his significant contributions to pharmacology and oncology research. His work appears in top-tier journals with 36.8% of his publications classified in Q1/D1 categories according to SCImago metrics.
Professor Halmos specializes in receptor pharmacology and experimental oncology, with particular expertise in kidney cancer, uveal melanoma, and growth hormone-related signaling pathways. His research focuses on identifying novel biomarkers, studying molecular mechanisms in renal cell carcinoma, and developing targeted cancer therapies using natural compounds like quercetin. His work bridges pharmaceutical sciences with clinical oncology, aiming to translate laboratory findings into improved cancer treatments. The Department of Biopharmacy under his leadership maintains strong research output with significant international collaborations.
Analysis of his recent publications (2023-2025) reveals a strong focus on molecular oncology, particularly in kidney cancer research where he investigates microRNA expression patterns, angiogenesis markers, and tumor biomarkers like IDO and PTEN. His collaborative work with international researchers, including Schally Andrew Victor (198 co-authored papers), demonstrates his significant standing in the field of receptor pharmacology and cancer therapeutics. His research spans multiple high-impact categories including Oncology (70 publications), Medicine (106), and Biochemistry, Genetics and Molecular Biology (93).
- Medicine (106 publications)
- Oncology (70 publications)
- Biochemistry, Genetics and Molecular Biology (93 publications)
- Pharmacology, Toxicology and Pharmaceutics (21 publications)
As Head of Department and Vice Dean, Professor Halmos mentors numerous students and researchers while leading his research team in investigating novel therapeutic approaches for various cancers. His laboratory focuses particularly on molecular pathways in renal cell carcinoma and melanoma, with emphasis on identifying potential targets for intervention and developing natural compound-based therapies. His ongoing research continues to contribute significantly to the understanding of cancer biology and potential therapeutic interventions.
